Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A Study of Trastuzumab Emtansine Versus Capecitabine + Lapatinib in Participants With HER2-positive Locally Advanced or Metastatic Breast Cancer (EMILIA)

10. September 2016 aktualisiert von: Hoffmann-La Roche

A Randomized, Multicenter, Phase III Open-label Study of the Efficacy and Safety of Trastuzumab MCC-DM1 vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy

This is a Phase III, randomized, multicenter, international, 2-arm, open-label clinical trial designed to compare the safety and efficacy of trastuzumab emtansine (T-DM1) with that of capecitabine + lapatinib in participants with human epidermal growth factor receptor 2 (HER2)-positive locally advanced or metastatic breast cancer. Participants will be treated until disease progression (PD), unmanageable toxicity, or study termination. Once disease progression is reported, all participants will be followed for survival every 3 months until death, loss to follow-up, withdrawal of consent, or study termination.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

991

Phase

  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

  • Bosnien und Herzegowina
      • Banja Luka, Bosnien und Herzegowina, 78000
      • Sarajewo, Bosnien und Herzegowina, 71000
  • Brasilien
      • Belo Horizonte, Brasilien, 30150-281
      • Curitiba, Brasilien, 80530-010
      • Goiania, Brasilien, 74605-070
      • Itajai, Brasilien, 88301-220
      • JAU, Brasilien, 17210-080
      • Joao Pessoa, Brasilien, 58040280
      • Porto Alegre, Brasilien, 90610-000
      • Porto Alegre, Brasilien, 91350-200
      • Porto Alegre, Brasilien, 90430-090
      • Porto Alegre - Rs, Brasilien, 90050-170
      • Rio de Janeiro, Brasilien, 20560-120
      • Rio de Janeiro, Brasilien, 22260-020
      • Santo Andre, Brasilien, 09060-870
      • Sao Paulo, Brasilien, 1323020
      • Sao Paulo, Brasilien, 01317-000
  • Bulgarien
      • Plovdiv, Bulgarien, 4000
      • Sofia, Bulgarien, 1756
      • Sofia, Bulgarien, 1784
      • Varna, Bulgarien, 9002
  • Deutschland
      • Aschaffenburg, Deutschland, 63739
      • Berlin, Deutschland, 10367
      • Berlin, Deutschland, 13125
      • Berlin, Deutschland, 4169
      • Bonn, Deutschland, 53113
      • Dortmund, Deutschland, 44137
      • Freiburg, Deutschland, 79106
      • Fuerstenwalde, Deutschland, 15517
      • Hamburg, Deutschland, 20357
      • Karlsruhe, Deutschland, 76135
      • Kiel, Deutschland, 24105
      • Offenbach, Deutschland, 63069
      • Stralsund, Deutschland, 18435
  • Dänemark
      • Herlev, Dänemark, 2730
      • København, Dänemark, 2100
      • Odense, Dänemark, 5000
  • Finnland
      • Helsinki, Finnland, 00180
      • Tampere, Finnland, 33520
      • Turku, Finnland, 20520
  • Frankreich
      • Avignon, Frankreich, 84082
      • Bordeaux, Frankreich, 33076
      • Brest, Frankreich, 29609
      • Caen, Frankreich, 14076
      • Dijon, Frankreich, 21079
      • La Roche Sur Yon, Frankreich, 85925
      • Montpellier, Frankreich, 34298
      • Paris, Frankreich, 75248
      • Saint Brieuc, Frankreich, 22015
      • Saint Herblain, Frankreich, 44805
      • Vandoeuvre-les-nancy, Frankreich, 54511
  • Hongkong
      • Hong Kong, Hongkong
  • Indien
      • Bangalore, Indien, 560027
      • Gurgaon, Indien, 122001
      • Kolkata, Indien, 700 053
      • New Delhi, Indien, 110029
      • Pune, Indien, 411004
  • Italien
      • Aviano, Italien, 33081
      • Bologna, Italien, 40138
      • Candiolo, Italien, 10060
      • Genova, Italien, 16132
      • Meldola, Italien, 47014
      • Milano, Italien, 20133
      • Milano, Italien, 20141
      • Napoli, Italien, 80131
      • Negrar, Italien, 37024
      • Pisa, Italien, 56100
      • Reggio Emilia, Italien, 42100
      • Roma, Italien, 00168
      • Rozzano, Italien, 20089
      • Sassari, Italien, 07100
      • Terni, Italien, 05100
  • Kanada
    • Alberta
      • Calgary, Alberta, Kanada, T2N 4N2
      • Edmonton, Alberta, Kanada, T6G 1Z2
    • British Columbia
      • Kelowna, British Columbia, Kanada, V1Y 5L3
      • Vancouver, British Columbia, Kanada, V5Z 1H5
    • Nova Scotia
      • Halifax, Nova Scotia, Kanada, B3H 2Y9
    • Ontario
      • Ottawa, Ontario, Kanada, K1H 8L6
      • Sudbury, Ontario, Kanada, J9P 3Y1
      • Toronto, Ontario, Kanada, M4N 3M5
    • Quebec
      • Greenfield Park, Quebec, Kanada, J4V 2H1
      • Montreal, Quebec, Kanada, H1T 2M4
      • Montreal, Quebec, Kanada, H3T 1E2
      • Montreal, Quebec, Kanada, H2W 1T8
  • Kolumbien
      • Bogota, Kolumbien
      • Bogota, Kolumbien, 49 00
      • Monteria, Kolumbien
  • Korea, Republik von
      • Kyunggi-do, Korea, Republik von, 411-769
      • Seoul, Korea, Republik von, 110-744
      • Seoul, Korea, Republik von, 120-752
      • Seoul, Korea, Republik von, 135-710
  • Mexiko
      • Acapulco, Mexiko, 39670
      • Oaxaca, Mexiko, 68000
      • Toluca, Mexiko, 50180
  • Neuseeland
      • Newtown, Neuseeland, 6021
      • Palmerston North, Neuseeland, 4442
  • Philippinen
      • Diliman, Quezon City, Philippinen, 1100
      • Quezon City, Luzon, Philippinen, 1101
  • Polen
      • Bialystok, Polen, 15-027
      • Gdansk, Polen, 80-952
      • Krakow, Polen, 31-531
      • Lublin, Polen, 20-090
      • Opole, Polen, 45-060
      • Poznan, Polen, 61-866
      • Warszawa, Polen, 02-781
  • Portugal
      • Coimbra, Portugal, 3000-075
      • Lisboa, Portugal, 1649-035
      • Porto, Portugal, 4200-072
  • Russische Föderation
      • Kemerovo, Russische Föderation, 650036
      • Moscow, Russische Föderation, 121356
      • St Petersburg, Russische Föderation, 197758
  • Schweden
      • Eskilstuna, Schweden, 63188
      • Gaelve, Schweden, 80187
      • Goteborg, Schweden, 40036
  • Schweiz
      • Luzern, Schweiz, 6004
      • St. Gallen, Schweiz, 9007
  • Singapur
      • Singapore, Singapur, 119074
      • Singapore, Singapur, 169610
  • Slowenien
      • Ljubljana, Slowenien, 1000
  • Spanien
      • Barcelona, Spanien, 08035
      • Córdoba, Spanien, 14004
      • Lerida, Spanien, 25198
      • Madrid, Spanien, 28046
      • Madrid, Spanien, 28041
      • Santander, Spanien, 39008
      • Sevilla, Spanien, 41013
      • Valencia, Spanien, 46009
      • Zaragoza, Spanien, 50009
  • Taiwan
      • Kaohsung, Taiwan, 883
      • Taichung, Taiwan, 404
      • Taichung, Taiwan, 407
      • Taipei, Taiwan, 112
      • Taoyuan, Taiwan, 333
  • Vereinigte Staaten
    • Arizona
      • Chandler, Arizona, Vereinigte Staaten, 85224
      • Tucson, Arizona, Vereinigte Staaten, 85719
    • California
      • Anaheim, California, Vereinigte Staaten, 92801
      • Anaheim, California, Vereinigte Staaten, 92807
      • Bakersfield, California, Vereinigte Staaten, 93309
      • Baldwin Park, California, Vereinigte Staaten, 91706
      • Bellflower, California, Vereinigte Staaten, 90706
      • Duarte, California, Vereinigte Staaten, 91010
      • Fontana, California, Vereinigte Staaten, 92335
      • Hayward, California, Vereinigte Staaten, 94545
      • Irvine, California, Vereinigte Staaten, 92618
      • La Jolla, California, Vereinigte Staaten, 92093
      • La Mesa, California, Vereinigte Staaten, 91942
      • Loma Linda, California, Vereinigte Staaten, 92354
      • Long Beach, California, Vereinigte Staaten, 90806
      • Los Angeles, California, Vereinigte Staaten, 90025
      • Los Angeles, California, Vereinigte Staaten, 90057
      • Los Angeles, California, Vereinigte Staaten, 90095-1772
      • Los Angeles, California, Vereinigte Staaten, 90034
      • Montebello, California, Vereinigte Staaten, 90640
      • Newport Beach, California, Vereinigte Staaten, 92660
      • Oakland, California, Vereinigte Staaten, 94611
      • Panorama City, California, Vereinigte Staaten, 91402
      • Riverside, California, Vereinigte Staaten, 92505
      • Roseville, California, Vereinigte Staaten, 95661
      • Sacramento, California, Vereinigte Staaten, 95825
      • San Diego, California, Vereinigte Staaten, 92123
      • San Diego, California, Vereinigte Staaten, 92120
      • San Francisco, California, Vereinigte Staaten, 94115
      • San Jose, California, Vereinigte Staaten, 95119
      • Santa Clara, California, Vereinigte Staaten, 95051
      • Santa Maria, California, Vereinigte Staaten, 93454
      • Santa Monica, California, Vereinigte Staaten, 90404
      • South San Francisco, California, Vereinigte Staaten, 94080
      • Thousand Oaks, California, Vereinigte Staaten, 91360
      • Vallejo, California, Vereinigte Staaten, 94589
      • Walnut Creek, California, Vereinigte Staaten, 94596
      • Woodland Hills, California, Vereinigte Staaten, 91367
    • Colorado
      • Fort Collins, Colorado, Vereinigte Staaten, 80528
    • Connecticut
      • Norwalk, Connecticut, Vereinigte Staaten, 06856
      • Norwich, Connecticut, Vereinigte Staaten, 06360
      • Stamford, Connecticut, Vereinigte Staaten, 06902
    • District of Columbia
      • Washington, District of Columbia, Vereinigte Staaten, 20010
    • Florida
      • Boca Raton, Florida, Vereinigte Staaten, 33486
      • Fernandina Beach, Florida, Vereinigte Staaten, 32034
      • Fort Myers, Florida, Vereinigte Staaten, 33916
      • Ft. Lauderdale, Florida, Vereinigte Staaten, 33316
      • Hollywood, Florida, Vereinigte Staaten, 33021
      • Jacksonville, Florida, Vereinigte Staaten, 32205
      • Jacksonville, Florida, Vereinigte Staaten, 32256
      • Jacksonville, Florida, Vereinigte Staaten, 32207
      • Jacksonville, Florida, Vereinigte Staaten, 32258
      • Kissimmee, Florida, Vereinigte Staaten, 34741
      • Lakeland, Florida, Vereinigte Staaten, 33804-1057
      • Miami, Florida, Vereinigte Staaten, 33136
      • Miami, Florida, Vereinigte Staaten, 33176
      • Miami, Florida, Vereinigte Staaten, 33133
      • Orange Park, Florida, Vereinigte Staaten, 32073
      • Pembroke Pines, Florida, Vereinigte Staaten, 33028
    • Georgia
      • Athens, Georgia, Vereinigte Staaten, 30607
      • Atlanta, Georgia, Vereinigte Staaten, 30342
      • Atlanta, Georgia, Vereinigte Staaten, 30322
      • Atlanta, Georgia, Vereinigte Staaten, 30341
      • Atlanta, Georgia, Vereinigte Staaten, 30318
      • Carrolton, Georgia, Vereinigte Staaten, 30117
      • Cartersville, Georgia, Vereinigte Staaten, 30121
      • Decatur, Georgia, Vereinigte Staaten, 30033
      • Douglasville, Georgia, Vereinigte Staaten, 30134
      • Macon, Georgia, Vereinigte Staaten, 31217
      • Marietta, Georgia, Vereinigte Staaten, 30060
    • Idaho
      • Boise, Idaho, Vereinigte Staaten, 83712
      • Meridian, Idaho, Vereinigte Staaten, 83642
      • Nampa, Idaho, Vereinigte Staaten, 83686
      • Post Falls, Idaho, Vereinigte Staaten, 83854
      • Twin Falls, Idaho, Vereinigte Staaten, 83301
    • Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60612
      • Decatur, Illinois, Vereinigte Staaten, 62526
      • Effingham, Illinois, Vereinigte Staaten, 62526
      • Joliet, Illinois, Vereinigte Staaten, 60435
      • Morris, Illinois, Vereinigte Staaten, 60450
      • Peoria, Illinois, Vereinigte Staaten, 61615-7828
      • Skokie, Illinois, Vereinigte Staaten, 60076
      • Zion, Illinois, Vereinigte Staaten, 60099
    • Iowa
      • Bettendorf, Iowa, Vereinigte Staaten, 52722
    • Kansas
      • Wichita, Kansas, Vereinigte Staaten, 67214-3728
    • Kentucky
      • Paducah, Kentucky, Vereinigte Staaten, 42001
    • Louisiana
      • Covington, Louisiana, Vereinigte Staaten, 70433
      • Lafayette, Louisiana, Vereinigte Staaten, 70503
      • Marrero, Louisiana, Vereinigte Staaten, 70072
      • Metairie, Louisiana, Vereinigte Staaten, 70006
      • New Orleans, Louisiana, Vereinigte Staaten, 70115
    • Maine
      • Kittery, Maine, Vereinigte Staaten, 03904
      • Wells, Maine, Vereinigte Staaten, 04090
      • York, Maine, Vereinigte Staaten, 03909
    • Maryland
      • Baltimore, Maryland, Vereinigte Staaten, 21202
      • Baltimore, Maryland, Vereinigte Staaten, 21237
      • Bethesda, Maryland, Vereinigte Staaten, 20817
      • Rockville, Maryland, Vereinigte Staaten, 20850
    • Massachusetts
      • Boston, Massachusetts, Vereinigte Staaten, 02215
      • Boston, Massachusetts, Vereinigte Staaten, 02114
      • Boston, Massachusetts, Vereinigte Staaten, 02118
      • Boston, Massachusetts, Vereinigte Staaten, 02115
      • Burlington, Massachusetts, Vereinigte Staaten, 01805
      • Peabody, Massachusetts, Vereinigte Staaten, 01960
    • Michigan
      • Brownstown, Michigan, Vereinigte Staaten, 48183
      • Dearborn, Michigan, Vereinigte Staaten, 48126
      • Detroit, Michigan, Vereinigte Staaten, 48201
      • Detroit, Michigan, Vereinigte Staaten, 48202
      • Saint Joseph, Michigan, Vereinigte Staaten, 49085
      • West Bloomfield, Michigan, Vereinigte Staaten, 48322
    • Minnesota
      • Edina, Minnesota, Vereinigte Staaten, 55414
      • Maplewood, Minnesota, Vereinigte Staaten, 55109
      • Minneapolis, Minnesota, Vereinigte Staaten, 55454
      • Saint Louis Park, Minnesota, Vereinigte Staaten, 55426
      • Saint Paul, Minnesota, Vereinigte Staaten, 55101
      • St. Louis Park, Minnesota, Vereinigte Staaten, 55426
    • Missouri
      • Joplin, Missouri, Vereinigte Staaten, 64804
      • Kansas City, Missouri, Vereinigte Staaten, 64111
      • Saint Louis, Missouri, Vereinigte Staaten, 63110
      • Saint Peters, Missouri, Vereinigte Staaten, 63110
      • St. Louis, Missouri, Vereinigte Staaten, 63141
      • St. Peters, Missouri, Vereinigte Staaten, 63376
    • Montana
      • Missoula, Montana, Vereinigte Staaten, 59802
    • Nebraska
      • Omaha, Nebraska, Vereinigte Staaten, 68114
    • Nevada
      • Henderson, Nevada, Vereinigte Staaten, 89052
    • New Jersey
      • Cherry Hill, New Jersey, Vereinigte Staaten, 08002
      • Hackensack, New Jersey, Vereinigte Staaten, 07601
      • Morristown, New Jersey, Vereinigte Staaten, 07962
      • Parsippany, New Jersey, Vereinigte Staaten, 07054
      • Voorhees, New Jersey, Vereinigte Staaten, 08043
    • New Mexico
      • Santa Fe, New Mexico, Vereinigte Staaten, 87505
    • New York
      • Brockport, New York, Vereinigte Staaten, 14420
      • Canandaigua, New York, Vereinigte Staaten, 14424
      • Fresh Meadows, New York, Vereinigte Staaten, 11366
      • Geneva, New York, Vereinigte Staaten, 14456
      • Greece, New York, Vereinigte Staaten, 14626
      • Lake Success, New York, Vereinigte Staaten, 11042
      • Mount Kisco, New York, Vereinigte Staaten, 10549
      • Rochester, New York, Vereinigte Staaten, 14626
      • Stony Brook, New York, Vereinigte Staaten, 11794
    • North Carolina
      • Charlotte, North Carolina, Vereinigte Staaten, 28203
      • Durham, North Carolina, Vereinigte Staaten, 27710
      • Hickory, North Carolina, Vereinigte Staaten, 28602
      • Kinston, North Carolina, Vereinigte Staaten, 28501
      • Washington, North Carolina, Vereinigte Staaten, 27889
    • Ohio
      • Cleveland, Ohio, Vereinigte Staaten, 44195
      • Cleveland, Ohio, Vereinigte Staaten, 44106
      • Columbus, Ohio, Vereinigte Staaten, 43215
      • Columbus, Ohio, Vereinigte Staaten, 43219
      • Columbus, Ohio, Vereinigte Staaten, 43228
      • Middletown, Ohio, Vereinigte Staaten, 45042
      • Newark, Ohio, Vereinigte Staaten, 43055
      • Sandusky, Ohio, Vereinigte Staaten, 44870
    • Oregon
      • Portland, Oregon, Vereinigte Staaten, 97227
    • Pennsylvania
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19124
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19106
      • Pittsburgh, Pennsylvania, Vereinigte Staaten, 15232
      • Pittsburgh, Pennsylvania, Vereinigte Staaten, 15213
    • Rhode Island
      • East Providence, Rhode Island, Vereinigte Staaten, 02915
    • South Carolina
      • Columbia, South Carolina, Vereinigte Staaten, 29210
      • North Charleston, South Carolina, Vereinigte Staaten, 29425
    • Tennessee
      • Memphis, Tennessee, Vereinigte Staaten, 38120
      • Nashville, Tennessee, Vereinigte Staaten, 37203
    • Texas
      • Austin, Texas, Vereinigte Staaten, 78731
      • Bryan, Texas, Vereinigte Staaten, 77802
      • Cypress, Texas, Vereinigte Staaten, 77429
      • Dallas, Texas, Vereinigte Staaten, 75230
      • El Paso, Texas, Vereinigte Staaten, 79902
      • Houston, Texas, Vereinigte Staaten, 77090
      • Shenandoah, Texas, Vereinigte Staaten, 77384
      • Temple, Texas, Vereinigte Staaten, 76501
    • Virginia
      • Fairfax, Virginia, Vereinigte Staaten, 22031
    • Washington
      • Gig Harbor, Washington, Vereinigte Staaten, 98332
      • Lakewood, Washington, Vereinigte Staaten, 98499
      • Puyallup, Washington, Vereinigte Staaten, 98372
      • Tacoma, Washington, Vereinigte Staaten, 98405
    • Wisconsin
      • Milwaukee, Wisconsin, Vereinigte Staaten, 53226
      • Wausau, Wisconsin, Vereinigte Staaten, 54401
  • Vereinigtes Königreich
      • Bournemouth, Vereinigtes Königreich, BH7 7DW
      • Cardiff, Vereinigtes Königreich, CF14 2TL
      • Denbigh, Vereinigtes Königreich, LL18 5UJ
      • London, Vereinigtes Königreich, SE1 7EH
      • London, Vereinigtes Königreich, SW3 6JJ
      • Manchester, Vereinigtes Königreich, M20 4BX
      • New Castle Upon Tyne, Vereinigtes Königreich, NE7 7DN
      • Northwood, Vereinigtes Königreich, HA6 2RN
      • Poole, Vereinigtes Königreich, BH15 2JB
      • Preston, Vereinigtes Königreich, PR2 9HT
      • Romford, Vereinigtes Königreich, RM7 0AG
      • Sutton, Vereinigtes Königreich, SM2 5PT
      • Weston Super Mare, Vereinigtes Königreich, BS23 4TQ

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • HER2 status must be prospectively, centrally tested and be HER2-positive based on central laboratory assay results
  • Histologically or cytologically confirmed invasive breast cancer
  • Prior treatment for breast cancer in the adjuvant, unresectable, locally advanced, or metastatic setting must include both a taxane, alone or in combination with another agent, and trastuzumab, alone or in combination with another agent
  • Documented progression (which occur during or after most recent treatment or within 6 months after completing of adjuvant therapy) of incurable, unresectable, locally advanced or metastatic breast cancer, defined by the investigator
  • Measurable and/or nonmeasurable disease; participants with central nervous system-only disease are excluded
  • Cardiac ejection fraction greater than or equal to (>/=) 50 percent (%) by either echocardiogram or multi-gated acquisition scan
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective, non-hormonal form of contraception; contraception use should continue for the duration of the study treatment and for at least 6 months after the last dose of study treatment

Exclusion Criteria:

  • History of treatment with trastuzumab emtansine
  • Prior treatment with lapatinib or capecitabine
  • Peripheral neuropathy of Grade >/= 3 per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 3.0
  • History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage 1 uterine cancer, synchronous or previously diagnosed HER2-positive breast cancer, or cancers with a similar curative outcome as those mentioned above
  • History of receiving any anti-cancer drug/biologic or investigational treatment within 21 days prior to randomization except hormone therapy, which could be given up to 7 days prior to randomization; recovery of treatment-related toxicity consistent with other eligibility criteria
  • History of radiation therapy within 14 days of randomization
  • Brain metastases that are untreated, symptomatic, or require therapy to control symptoms, as well as any history of radiation, surgery, or other therapy, including steroids, to control symptoms from brain metastases within 2 months (60 days) of randomization
  • History of symptomatic congestive heart failure or serious cardiac arrhythmia requiring treatment
  • History of myocardial infarction or unstable angina within 6 months of randomization
  • Current dyspnea at rest due to complications of advanced malignancy or current requirement for continuous oxygen therapy
  • Current severe, uncontrolled systemic disease (for example, clinically significant cardiovascular, pulmonary, or metabolic disease)
  • Pregnancy or lactation
  • Current known active infection with human immunodeficiency virus (HIV), hepatitis B virus, or hepatitis C virus
  • Presence of conditions that could affect gastrointestinal absorption: Malabsorption syndrome, resection of the small bowel or stomach, and ulcerative colitis
  • History of intolerance (such as Grade 3-4 infusion reaction) to trastuzumab
  • Known hypersensitivity to 5-fluorouracil or known dihydropyrimidine dehydrogenase deficiency
  • Current treatment with sorivudine or its chemically related analogs, such as brivudine

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Trastuzumab emtansine
Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenous (IV) infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle until disease progression (PD) (as assessed by the investigator), unmanageable toxicity, or study termination.
Arzneimittel: Trastuzumab emtansine
Trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle.
Andere Namen:
  • RO5304020
  • T-DM1
  • Trastuzumab-MCC-DM1
Aktiver Komparator: Lapatinib + Capecitabine
Participants will receive lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle + capecitabine 1000 milligrams per square meter (mg/m^2) orally twice daily on Days 1-14 of each 21-day treatment cycle until PD (as assessed by the investigator), unmanageable toxicity, or study termination. Eligible participants will cross over to receive trastuzumab emtansine if second interim analysis demonstrates statistically significant overall survival benefit in favor of trastuzumab emtansine.
Arzneimittel: Lapatinib
Lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle.
Andere Namen:
  • Tykerb
  • Tyverb
Arzneimittel: Capecitabine
Capecitabine 1000 mg/m^2 orally twice daily on Days 1-14 of each 21-day treatment cycle.
Andere Namen:
  • Xeloda

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Percentage of Participants With PD or Death as Assessed by an Independent Review Committee (IRC)
Zeitfenster: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
PD was assessed by an IRC using modified Response Evaluation Criteria in Solid Tumors (RECIST). All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as target lesions (TLs) and recorded at baseline. TLs should be selected on the basis of their size (those with the longest diameter) and their suitability for accurate repeated measurements either by imaging or clinically. A sum of the longest diameter for all TLs was calculated as baseline sum longest diameter (SLD). All other lesions (or sites of disease) should be identified as non-TLs and recorded at baseline. PD for TLs was defined as greater than or equal to (>/=) 20 percent (%) increase in SLD, taking as reference smallest SLD recorded since treatment started or appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Percentage of Participants with PD by IRC or death from any cause was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Progression-free Survival (PFS) as Assessed by an IRC (Co-primary Endpoint)
Zeitfenster: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs (on the basis of their size and their suitability for accurate repeated measurements either by imaging or clinically) and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. All other lesions were identified as non-TLs and recorded at baseline. PD for TLs: >/= 20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or appearance of 1 or more new lesions. PD for non-TLs: appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. PFS: time from randomization to first documented PD by IRC or death from any cause (whichever occurred earlier). The median duration of PFS was estimated using Kaplan-Meier method. The 95% confidence interval (CI) was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants Who Died: Second Interim Analysis
Zeitfenster: From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
The percentage of participants who died from any cause was reported. The results are reported from second interim analysis, which deemed to be the confirmatory.
From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
Overall Survival: Second Interim Analysis (Co-primary Endpoint)
Zeitfenster: From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
OS was defined as the time from the date of randomization to the date of death from any cause. The median duration of OS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley. The results are reported from second interim analysis, which deemed to be the confirmatory.
From the date of randomization through the data cut-off date of 31 Jul 2012 (up to 3 years, 5 months)
Percentage of Participants Who Died: Final Analysis
Zeitfenster: From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
The percentage of participants who died from any cause was reported. The results reported are from the final analysis. The final analysis is descriptive.
From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
Overall Survival: Final Analysis
Zeitfenster: From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
OS was defined as the time from the date of randomization to the date of death from any cause. The median duration of OS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley. The results reported are from the final analysis. The final analysis is descriptive.
From the date of randomization through the data cut-off date of 31 Dec 2014 (up to 5 years, 11 months)
Percentage of Participants Who Were Alive at Year 1
Zeitfenster: Year 1
1 year survival was defined as the percentage of participants alive 1 year after starting treatment. The results reported are from the final analysis.
Year 1
Percentage of Participants Who Were Alive at Year 2
Zeitfenster: Year 2
2 year survival was defined as the percentage of participants alive 2 years after starting treatment. The results reported are from the final analysis.
Year 2

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Percentage of Participants With PD or Death as Assessed by the Investigator
Zeitfenster: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
PD was assessed by the investigator using modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. PD for TLs was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The percentage of participants who died or experienced PD by Investigator was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
PFS as Assessed by the Investigator
Zeitfenster: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by the investigator according to modified RECIST. All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. PD for TLs was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. PD for non-TLs was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. PFS was defined as the time from randomization to first documented PD by Investigator or death from any cause (whichever occurred earlier). The median duration of PFS was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Objective Response (OR) as Assessed by an IRC
Zeitfenster: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. OR was defined as the percentage of participants with a complete response (CR) or partial response (PR). All measurable lesions up to a maximum of 5 per organ and 10 in total were identified as TLs and recorded at baseline. A sum of the longest diameter for all TLs was calculated as baseline SLD. For TLs, a CR was defined as the disappearance of all TLs and a PR was defined as >/= 30% decrease in the SLD of TLs, taking as reference the baseline SLD. For non-TLs, a CR was defined as the disappearance of all non-TLs and a PR was defined as the persistence of 1 or more non-TLs. Confirmation of response at a consecutive tumor assessment at least 4 weeks apart was required. Participants without a post-baseline tumor assessment were considered non-responders. The percentage of participants with CR or PR by IRC was reported. The 95% CI was computed using Blyth-Still Casella exact CI method.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Duration of Objective Response (DOR) as Assessed by an IRC
Zeitfenster: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. DOR was defined as the time from first documented OR to first documented PD or death from any cause, whichever occurred earlier. OR was defined as a CR or PR determined on 2 consecutive tumor assessments at least 4 weeks apart. For TLs, CR was defined as the disappearance of all TLs; PR was defined as >/=30% decrease in the SLD of TLs, taking as reference the baseline SLD; and PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, CR was defined as the disappearance of all non-TLs; PR was defined as the persistence of 1 or more non-TLs; and PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Clinical Benefit as Assessed by an IRC
Zeitfenster: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Tumor response was assessed by an IRC according to modified RECIST. Participants were considered as experienced clinical benefit if they had an OR or maintained stable disease (SD) for at least 6 months from randomization. OR: CR or PR determined on 2 consecutive tumor assessments >/=4 weeks apart. For TLs, CR: disappearance of all TLs; PR: >/=30% decrease in the SLD of TLs, taking as reference the baseline SLD; PD: >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or appearance of 1 or more new lesions; and SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. For non-TLs, CR: disappearance of all non-TLs; PR/SD: persistence of 1 or more non-TLs; and PD: appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Participants without a post-baseline tumor assessment were considered non-responders. The 95% CI was computed using Blyth-Still Casella exact CI method.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Treatment Failure
Zeitfenster: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Treatment failure was defined as discontinuation of treatment for any reason, including PD (per investigator review), treatment toxicity, or death from any cause. For "Lapatinib + Capecitabine" arm, a participant was considered as treatment failure only if both drugs were discontinued. For TLs, PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. Percentage of participants with treatment failure was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to Treatment Failure
Zeitfenster: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to treatment failure was defined as the time from randomization to discontinuation of treatment for any reason, including PD (per investigator review), treatment toxicity, or death from any cause. For "Lapatinib + Capecitabine" arm, a participant was considered as treatment failure only if both drugs were discontinued with treatment failure date as the later of the 2 discontinuation dates. For TLs, PD was defined as >/=20% increase in the SLD, taking as reference the smallest SLD recorded since treatment started or the appearance of 1 or more new lesions. For non-TLs, PD was defined as appearance of 1 or more new lesions and/or unequivocal progression of existing non-TLs. The median time to treatment failure was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Percentage of Participants With Symptom Progression
Zeitfenster: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Symptom progression was defined as the documentation of a >/= 5-point decrease from baseline in the scoring of responses as measured by the Functional Assessment of Cancer Therapy-for participants with Breast Cancer (FACT-B) questionnaire with the Trial Outcomes Index-Physical/Functional/Breast (TOI-PFB) subscale. The FACT-B TOI-PFB subscale contained 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer participants (breast cancer subscale [BCS]). All items in the questionnaire were rated by the participant on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96 with higher score indicating better perceived quality of life. The percentage of participants with symptom progression was reported.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to Symptom Progression
Zeitfenster: From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)
Time to symptom progression was defined as the time from randomization to the first documentation of a >/= 5-point decrease from baseline in the scoring of responses as measured by the FACT-B questionnaire with the TOI-PFB subscale. The FACT-B TOI-PFB subscale contained 24 items from 3 subsections of the FACT-B questionnaire: Physical well-being, functional well-being, and additional concerns for breast cancer participants (BCS). All items in the questionnaire were rated by the participant on a 5-point scale ranging from 0 ("not at all") to 4 ("very much"). The total score ranged from 0 to 96 with higher score indicating better perceived quality of life. The median time to symptom progression was estimated using Kaplan-Meier method. The 95% CI was computed using the method of Brookmeyer and Crowley.
From the date of randomization through the data cut-off date of 14 Jan 2012 (up to 2 years, 11 months)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Hoffmann-La Roche

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Allgemeine Veröffentlichungen

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn

1. Februar 2009

Primärer Abschluss (Tatsächlich)

1. Juli 2012

Studienabschluss (Tatsächlich)

1. September 2015

Studienanmeldedaten

Zuerst eingereicht

22. Januar 2009

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

22. Januar 2009

Zuerst gepostet (Schätzen)

26. Januar 2009

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Schätzen)

31. Oktober 2016

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

10. September 2016

Zuletzt verifiziert

1. September 2016

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • BO21977
  • TDM4370g (Andere Kennung: Genentech)

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Brustkrebs

Klinische Studien zur Trastuzumab emtansine

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Netherlands

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren